YOKNEAM, Israel, Aug. 6, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events in August:
9th Annual Needham Virtual MedTech & Diagnostics Conference
Presenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer
Format: Virtual one-on-one meetings
When: Monday, Aug. 12
Canaccord 44th Annual Global Growth Conference
Presenters: Yair Malca, Chief Financial Officer
Format: In-person fireside chat moderated by Caitlin Cronin, Director of MedTech Equity Research, and meetings
When: Wednesday, Aug. 14 at 2:00 pm ET
A live webcast of the presentation can be accessed here.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
Investor Relations Contact:
Miri Segal-Scharia
MS-IR LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
917-607-8654
| Last Trade: | US$18.01 |
| Daily Change: | -0.99 -5.21 |
| Daily Volume: | 1,377,936 |
| Market Cap: | US$1.370B |
September 04, 2024 July 31, 2024 July 17, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
